Nemolizumab for LS
ConditionLichen Sclerosus of Vulva
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexFemale
Age18+
SponsorUniversity of Texas Southwestern Medical Center
About this trial
Patients ≥ 18 years of age with Lichen sclerosis (LS)
Eligibility criteria
Qualifiers
Ability to comprehend and willingness to sign a written
Females only ≥18 years of age at time of screening
Documentation of biopsy-proven anogenital LS.
Baseline itch NRS score ≥ 6 in anogenital area.
Disqualifiers
Participants who do not have LS involving anogenital area.
Need for receiving a live vaccine right before or during treatment with the study drug.
Planned or expected major surgical procedure during the clinical study.
Pregnant or lactating participants or those considering pregnancy during the period of their study participation.
Trial design
Treatments tested in this trial
- Nemolizumab 30 mg
Treatment groups
25 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov